Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine.
Sign Up to like & getrecommendations! Published in 2019 at "Blood reviews"
DOI: 10.1016/j.blre.2019.100618
Abstract: Patients with haemophilia A (HA) or B (HB) experience spontaneous limb- or life-threatening bleedings which are prevented by regular prophylactic intravenous infusions of the deficient coagulation factor (FVIII or FIX). Prophylaxis with subcutaneous long-acting non-factor… read more here.
Keywords: medicine; haemophilia; treatment; factor products ... See more keywords
Self-compatibility of Crataegus pinnatifida Bge. ‘Zizhenzhu’ is associated with the mutation of a pistil-part non-S factor
Sign Up to like & getrecommendations! Published in 2020 at "Scientia Horticulturae"
DOI: 10.1016/j.scienta.2020.109362
Abstract: Abstract ‘Zizhenzhu’ is a spontaneous, self-compatible hawthorn (Crataegus pinnatifida Bge.) mutant of unknown parentage. Although ‘Zinzhenzhu’ possesses typical S-RNase-based gametophytic self-incompatibility, the molecular mechanism underlying its self-compatible phenotype is still unclear. In this study, two… read more here.
Keywords: self compatibility; pinnatifida bge; crataegus pinnatifida; zizhenzhu ... See more keywords
Current and future therapies for haemophilia—Beyond factor replacement therapies
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18379
Abstract: Some non‐factor products that work by facilitating the coagulation pathway (emicizumab) and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for patients with haemophilia (H) have been developed, and clinical trials using these products are… read more here.
Keywords: factor products; factor; non factor; future therapies ... See more keywords